drugset / Trial / NCT00831649

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

NCT00831649

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)

Timeline

Start
2004-09
Primary completion
2005-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody Intravenous

Indications